PROF
Profound Medical Corp.
$6.63
-0.38%
$240.7M
No data for this timeframe.
Vol
Market Cap$240.7M
Cap SizeMicro Cap
Inst. Holders20 funds
Inst. Value$31.8M
Inst. Activity1 buys / 0 sells
SEC Reports5
Press Releases2
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. A6·CIK 0001628808·Prev Close $6.65
Recent Activity
May 14, 2026
SEC
Profound Medical issued a press release announcing that its TULSA Procedure will be featured in four oral presentations
8-K — Impact 3/10
May 12, 2026
SEC
Profound Medical filed an S-3 registration statement to register 921,428 common shares for resale by selling shareholder
S-3 — Impact 3/10
Apr 16, 2026
SEC
Profound Medical Corp. announced it will release its first quarter 2026 financial results on May 7, 2026, after market c
8-K — Impact 3/10
Inst.
TD Waterhouse Canada Inc. — ADD
143,041 shares ($902.0K)
Inst.
BANK OF AMERICA CORP — NEAR_EXIT
96 shares ($756.00)
Apr 14, 2026
other
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
<p align="justify">TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.
Apr 1, 2026
Press
Profound Medical announced that its TULSA-PRO system and the MRI-guided TULSA Procedure will be featured in multiple pre
Impact 3/10
Mar 5, 2026
Press
Profound Medical reported record Q4 and full-year 2025 results, with Q4 revenue up 43% YoY to $6.0 million, driven by st
Impact 6/10
Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$11.14 (Jan 2026)
Current $6.63
Low $10.00
Median $11.20
High $12.00
5 analysts
$10.00
$12.00
Analyst Ratings
1Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jan 7, 2026 | Lake Street | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.24 ▲ +3.8% | $-0.29 — $-0.19 | 53% YoY | 4 |
| Next Q | $-0.24 ▼ -1.9% | $-0.26 — $-0.23 | 7% YoY | 4 |
| Current FY | $-0.84 ▲ +11.7% | $-0.92 — $-0.62 | 40% YoY | 5 |
| Next FY | $-0.75 ▲ +4.1% | $-1.48 — $-0.07 | 11% YoY | 5 |
Latest Reports
NEUTRAL
8-K
3/10
Profound Medical issued a press release announcing that its TULSA Procedure will be featured in four oral presentations
May 14, 2026
NEUTRAL
S-3
3/10
Profound Medical filed an S-3 registration statement to register 921,428 common shares for resale by selling shareholder
May 12, 2026
NEUTRAL
Press
3/10
Profound Medical announced that its TULSA-PRO system and the MRI-guided TULSA Procedure will be featured in multiple pre
Apr 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FIL Ltd | $15.2M | — |
| ROYCE & ASSOCIATES LP | $7.1M | ADD |
| ROYAL BANK OF CANADA | $3.2M | — |
| First Eagle Investment Management, | $2.1M | DOUBLED |
| NATIONAL BANK OF CANADA | $1.3M | — |
20 institutional holders with $31.8M total value (4,937,108 shares) as of 2026-Q1. Top holders: FIL, ROYCE, ROYAL. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FIL Ltd | 2,340,000 | $15.2M | 47.7% | — |
| 2 | ROYCE & ASSOCIATES LP | 1,116,348 | $7.1M | 22.5% | ADD +34.3% |
| 3 | ROYAL BANK OF CANADA | 493,060 | $3.2M | 10.0% | — |
| 4 | First Eagle Investment Management, LLC | 322,707 | $2.1M | 6.6% | DOUBLED +138.8% |
| 5 | NATIONAL BANK OF CANADA /FI/ | 217,175 | $1.3M | 4.2% | — |
| 6 | RAYMOND JAMES FINANCIAL INC | 150,157 | $973.0K | 3.1% | — |
| 7 | TD Waterhouse Canada Inc. | 143,041 | $902.0K | 2.8% | ADD +84.6% |
| 8 | HB Wealth Management, LLC | 30,000 | $194.4K | 0.6% | — |
| 9 | Centiva Capital, LP | 29,280 | $189.7K | 0.6% | — |
| 10 | CITADEL ADVISORS LLC | 21,400 | $138.7K | 0.4% | NEAR_EXIT -78.2% |
| 11 | GOLDMAN SACHS GROUP INC | 18,707 | $121.2K | 0.4% | — |
| 12 | CITADEL ADVISORS LLC | 13,200 | $85.5K | 0.3% | NEAR_EXIT -78.2% |
| 13 | BANK OF MONTREAL /CAN/ | 11,742 | $75.1K | 0.2% | — |
| 14 | CAPTRUST FINANCIAL ADVISORS | 10,398 | $67.4K | 0.2% | — |
| 15 | Rockefeller Capital Management L.P. | 6,654 | $43.1K | 0.1% | — |
| 16 | WELLS FARGO & COMPANY/MN | 5,592 | $36.2K | 0.1% | — |
| 17 | BlackRock, Inc. | 4,670 | $30.3K | 0.1% | — |
| 18 | MORGAN STANLEY | 1,929 | $12.5K | 0.0% | TRIM -48.3% |
| 19 | JONES FINANCIAL COMPANIES LLLP | 1,000 | $6.2K | 0.0% | — |
| 20 | Allworth Financial LP | 48 | $312.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TD Waterhouse Canada Inc. | ADD | 77,493 | 143,041 | +84.6% | $902.0K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 200,160 | 96 | -100.0% | $756.00 | 2025-Q4 |
| First Eagle Investment Management, LLC | DOUBLED | 122,039 | 291,391 | +138.8% | $1.5M | 2025-Q3 |
| TD Waterhouse Canada Inc. | ADD | 56,073 | 75,293 | +34.3% | $356.1K | 2025-Q3 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 46,310 | 10,073 | -78.2% | $50.2K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 3,734 | 1,929 | -48.3% | $9.4K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 3,755 | 202 | -94.6% | $988.00 | 2025-Q3 |
| TD Waterhouse Canada Inc. | ADD | 41,153 | 56,073 | +36.3% | $341.5K | 2025-Q2 |
| UBS Group AG | DOUBLED | 776 | 3,755 | +383.9% | $22.2K | 2025-Q2 |
| TD Waterhouse Canada Inc. | ADD | 25,402 | 41,153 | +62.0% | $234.5K | 2025-Q1 |
| MARSHALL WACE, LLP | TRIM | 36,216 | 20,801 | -42.6% | $121.1K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 7,789 | 5,234 | -32.8% | $30.5K | 2025-Q1 |
| ROYCE & ASSOCIATES LP | ADD | 569,298 | 764,799 | +34.3% | $5.7M | 2024-Q4 |
| MARSHALL WACE, LLP | DOUBLED | 12,008 | 36,216 | +201.6% | $272.0K | 2024-Q4 |
| MORGAN STANLEY | ADD | 4,534 | 7,789 | +71.8% | $58.5K | 2024-Q4 |
| TD Waterhouse Canada Inc. | ADD | 15,257 | 23,887 | +56.6% | $188.5K | 2024-Q3 |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | TRIM | 30,002 | 15,001 | -50.0% | $119.4K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.8/10.
NEUTRAL
8-K
3/10
Profound Medical issued a press release announcing that its TULSA Procedure will be featured in four
May 14, 2026
NEUTRAL
S-3
3/10
Profound Medical filed an S-3 registration statement to register 921,428 common shares for resale by
May 12, 2026
NEUTRAL
8-K
3/10
Profound Medical Corp. announced it will release its first quarter 2026 financial results on May 7,
Apr 16, 2026
NEUTRAL
8-K
3/10
Profound Medical announced it will present a business update at the 2026 Bloom Burton & Co. Healthca
Apr 14, 2026
BULLISH
8-K
7/10
Profound Medical reported strong Q4 and full-year 2025 results with 43% YoY revenue growth to $6.0 m
Mar 5, 2026
Historical analyst distribution (last covering-analyst action Jan 2026): 80% buy across 5 analysts — 1 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$11.14 mean target (Jan 2026)
$10.00 Low
$12.00 High
| Metric | Value |
|---|---|
| Current Price | $6.63 |
| Target Low | $10.00 |
| Target Mean | $11.14 |
| Target Median | $11.20 |
| Target High | $12.00 |
| # Analysts | 5 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.24 | $-0.29 | $-0.19 | 53.4% | +3.8% | 2↑ 2↓ | $0.0B | 113.9% | 4 |
| Next Q 2026-09-30 |
$-0.24 | $-0.26 | $-0.23 | 6.7% | -1.9% | 1↑ 3↓ | $0.0B | 20.4% | 4 |
| Current FY 2026-12-31 |
$-0.84 | $-0.92 | $-0.62 | 40.1% | +11.7% | 3↑ 2↓ | $0.0B | 62.0% | 5 |
| Next FY 2027-12-31 |
$-0.75 | $-1.48 | $-0.07 | 10.9% | +4.1% | 3↑ 2↓ | $0.1B | 69.7% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.242 | |
| 7d ago | $-0.237 | -0.005 |
| 30d ago | $-0.252 | +0.010 |
| 60d ago | $-0.252 | +0.010 |
| 90d ago | $-0.253 | +0.011 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jan 7, 2026 | Lake Street | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| May 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Apr 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Mar 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Feb 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% | |
| Jan 1, 2026 | 1 | 3 | 1 | 0 | 0 | 80% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Apr 14, 2026
other
Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
<p align="justify">TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=1aPABF3srsm7P_WvunU8RgC9Hyar8RG0I
Apr 1, 2026
fda
Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
<p align="justify">TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=MqKA1dSitc8sYXgush1gYudRJGgjMq7vT
Mar 27, 2026
other
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone
<p align="justify">TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=2sVO_sShLW1C8-p8jEb3KXUv3DvnplPd7
Mar 13, 2026
other
CAPTAIN Trial Comparing Profound’s MRI-Guided TULSA Procedure™ to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
<p align="center"><em>– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prosta
Mar 9, 2026
fda
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
<p align="justify">TORONTO, March 09, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=8RXWXi3t93kiVfYpmjN4T8ssnDX8IwpMs
Mar 9, 2026
short_interest
FTD: PROF — 119,448 shares ($0.6M) failed to deliver
Settlement: 20260309, Price: $5.31, FTD Value: $634,268.88, PROFOUND MED CORP COM NEW (CAN
Mar 5, 2026
earnings
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
<p align="justify">TORONTO, March 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=QuZTPTpZ0UM390dMcSib3jZq-Y498e6tp